Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMIBUW5)

Drug Name
GW-788388 Drug Info
Synonyms
452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW-788388; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606
Cross-matching ID
PubChem CID
10202642
ChEBI ID
CHEMBL202887
CAS Number
CAS 452342-67-5
TTD Drug ID
D0C3AD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.28 0.00e+0 34/36 (94.44%) POLE2;PRIM1;RFC5;...
Ribosome biogenesis in eukaryotes 1.98 4.79e-3 52/108 (48.15%) FBL;NXT2;POP7;...
Nucleotide excision repair 1.90 3.19e-3 40/47 (85.11%) POLE2;RFC5;POLE3;...
GABAergic synapse 1.83 2.63e-2 76/89 (85.39%) GNAI1;SLC38A1;GNG11;...
Ribosome 1.80 3.06e-2 113/158 (71.52%) MRPL12;MRPL18;RSL24D1;...
Mismatch repair 1.76 4.15e-2 22/23 (95.65%) MSH2;RFC5;RFC3;...
Hematopoietic cell lineage -1.61 4.82e-2 90/99 (90.91%) DNTT;GP1BB;ITGA6;...
Lysosome -1.61 4.89e-2 115/128 (89.84%) MAN2B1;SLC11A1;ATP6V0C;...
Synthesis and degradation of ketone bodies -1.64 4.15e-2 9/10 (90%) ACAT2;HMGCS2;HMGCS1
Terpenoid backbone biosynthesis -1.66 3.61e-2 18/22 (81.82%) GGPS1;PCYOX1;IDI1;...
Phototransduction -1.66 3.37e-2 21/29 (72.41%) PDE6A;PDE6G;GNAT2;...
Prostate cancer -1.67 3.55e-2 93/97 (95.88%) MMP3;MAPK3;RELA;...
Biosynthesis of unsaturated fatty acids -1.68 3.40e-2 21/27 (77.78%) ELOVL1;FADS2;ACOX1;...
Allograft rejection -1.72 2.56e-2 32/38 (84.21%) HLA-DQB1;HLA-DRB1;HLA-DPB1;...
Graft-versus-host disease -1.78 1.62e-2 32/42 (76.19%) IL1B;HLA-DQB1;HLA-DRB1;...
Epstein-Barr virus infection -1.78 1.66e-2 189/202 (93.56%) NFKB1;TYK2;MAP2K3;...
Tuberculosis -1.79 1.71e-2 159/180 (88.33%) ATP6V0C;AKT1;BCL10;...
Glycolysis / Gluconeogenesis -1.81 1.60e-2 56/67 (83.58%) HK1;ALDH7A1;ADH6;...
Intestinal immune network for IgA production -1.89 6.06e-3 38/48 (79.17%) CCR10;HLA-DMB;CXCR4;...
Antigen processing and presentation -1.91 4.72e-3 60/78 (76.92%) CD8A;CTSB;HSPA8;...
ECM-receptor interaction -1.92 5.19e-3 80/88 (90.91%) THBS1;SDC4;ITGA2;...
Protein digestion and absorption -1.93 5.77e-3 78/103 (75.73%) COL9A2;DPP4;COL1A1;...
Asthma -1.96 3.89e-3 25/31 (80.65%) FCER1G;HLA-DQB1;HLA-DRB1;...
Autoimmune thyroid disease -1.97 4.45e-3 46/53 (86.79%) HLA-DQB1;HLA-DRB1;HLA-DPB1;...
Bladder cancer -2.00 3.46e-3 40/41 (97.56%) CDKN2A;ERBB2;THBS1;...
Leishmaniasis -2.03 2.08e-3 67/77 (87.01%) IRAK4;HLA-DMB;FCGR2C;...
Primary immunodeficiency -2.03 2.60e-3 33/38 (86.84%) RFX5;BTK;CD19;...
Staphylococcus aureus infection -2.08 3.46e-3 72/95 (75.79%) DEFA6;ICAM1;KRT33A;...
Steroid biosynthesis -2.14 5.19e-3 19/20 (95%) HSD17B7;SOAT1;EBP;...
Phagosome -2.18 1.04e-2 118/152 (77.63%) ATP6V0C;THBS3;HLA-A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.11uM - 10uM 24H